| Name | Title | Contact Details |
|---|
Rayant is a Newark, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Manatee Diagnostic Ctr is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Bradenton, FL. To find more information about Manatee Diagnostic Ctr, please visit www.manateediagnostic.com
ACI Specialty Benefits Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BrightSpring Health Services is the new name for Kentucky-based ResCare, the parent company of a family of brands and services that provides both clinical and nonclinical habilitative care services for people of all ages and health and skill levels, across home and community settings. As care preferences and health care needs are changing, BrightSpring`s new name reflects the company`s evolution that began nearly two years ago to successfully meet the multifaceted and multidisciplinary requirements of the populations it serves amid this changing health care landscape. The path forward at BrightSpring is occurring through investments in capabilities, people, processes and technology to create an unprecedented and differentiated platform of innovative solutions that improve health outcomes and lower costs for complex populations and payer systems. ResCare has a rich history of more than 44 years – making a difference in the communities that it serves and helping people live their best lives. While celebrating the successful history, BrightSpring is repositioning itself for the future of health care. Its vision is to be the leading provider of comprehensive home and community-based health services to complex populations.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.